Genentech Reports Results of Tiragolumab + Tecentriq (atezolizumab) in P-II (CITYSCAPE) Trial for the Treatment of NSCLC
Shots:
- The P-II (CITYSCAPE) trial evaluates tiragolumab + Tecentriq vs Tecentriq alone in a ratio (1:1) in 135 patients with PD-L1-positive LA, unresectable or metastatic NSCLC
- The results showed an improvement in PFS & OS in the ITT population after 2.5yrs. of median follow-up with m-PFS (5.6mos. vs 3.9mos.) & m-OS (23.2mos. vs 14.5mos.); 38% reduction in risk of disease worsening or death (PFS); improvement in ORR (38.8% vs 20.6%)
- In a predefined exploratory analysis in the PD-L1-high population, 71% reduction in risk of disease worsening or death; m-PFS (16.6mos. vs 4.1mos.); ORR (69% vs 24.1%), improvement in OS & median was not reached, was generally well-tolerated
Ref: Businesswire | Image: Genentech
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com